A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Pomalidomide (Primary) ; Carbamazepine; Fluvoxamine; Ketoconazole
- Indications Bipolar disorders; Epilepsy; Graft-versus-host disease; Multiple myeloma; Myelofibrosis; Obsessive-compulsive disorders; Pancreatic cancer; Seborrhoeic dermatitis; Small cell lung cancer; Social phobia; Systemic scleroderma; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 08 Nov 2012 New trial record
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.